CMA proposes stricter transparency and information disclosure standards for investigations
The Competition and Markets Authority (CMA) published a consultation to update its general guidance on transparency and disclosure (CMA6). The revisions clarify how the CMA will handle confidential information and when it will use its powers under Part 9 of the Enterprise Act 2002 to disclose information to third parties or other authorities. This update reflects the CMA's refined approach to balancing transparency for effective markets with the protection of commercially sensitive data.
Telemetry is advisory — directional context, not a deterministic risk score.
Strategic Governance Impact
Structural governance significance — not general importance.
Important development
The UK Competition and Markets Authority is raising the threshold for companies to protect confidential information during investigations. This shift increases the risk of proprietary corporate data being shared with international regulators or the public. It alters how executives manage information risk and the governance of evidence during regulatory inquiries.
Exposure pathway
Legal and compliance departments of firms involved in UK-based mergers, market studies, or enforcement investigations are exposed through heightened expectations for justifying confidentiality claims. Operational risks arise from the potential for wider disclosure of business secrets to international regulators or the public during proceedings.
What may need to be proven
Regulated entities must provide clearer, substantiated justifications for information redaction and must maintain detailed logs of confidentiality claims that withstand CMA scrutiny. Broad, unevidenced assertions of commercial sensitivity are less likely to be accepted under the updated framework.
Operational consequence mapping
What this signal actually changes
- What operational condition changed?
- The threshold for maintaining confidentiality over business-sensitive information in competition cases is becoming more rigorous and structured.
Consequence analysis · premium
Full operational consequence mapping — actors exposed, broken assumptions, evidence expectations, operational burden — is reserved for Premium and Executive subscribers.
Request accessSource citation
UK GOV.UK Policy Papers
GRandCIndex monitors source publications without reproducing them verbatim. Original materials remain the authoritative reference.
Executive interpretation · premium
Premium subscribers receive structured interpretation: cross-jurisdictional read-across, board-level translation, and proof-exposure mapping linked to internal control taxonomy.
Request accessConvergent signals
Reinforcing pressure across different stories
- High2026-08-25US#antitrust#healthcare-regulation#mergers-and-acquisitions#ftc-enforcementSIG-2026-5E00RZStrongSteadyImmediateLegal
FTC Finalizes Consent Order for Ascension Health-AmSurg Acquisition
The Federal Trade Commission issued a final consent order governing Ascension Health Alliance’s $3.9 billion acquisition of AmSurg LLC. The order imposes structural and behavioral remedies to prevent anti-competitive consolidation in outpatient surgical services and healthcare labor markets.
+5 more reinforcing signals · premium
Pattern context
Related signals in the same risk surface
- Medium2026-08-25US#fda-authorization#medical-devices#digital-health#wearable-techSIG-2026-1HWYI5StrongEscalatingImmediateEngineering
FDA Authorizes First Wearable Dual Glucose and Ketone Continuous Monitoring System
The U.S. Food and Drug Administration (FDA) authorized the marketing of the Libre Duo 10 Day Continuous Dual Glucose-Ketone Monitoring System, the first wearable device capable of simultaneous, continuous tracking of both metrics. This de novo authorization establishes a new regulatory precedent for integrated metabolic monitoring devices intended for individuals aged two and older with diabetes.
+3 more related signals · premium